Home » Stocks » ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR)

Stock Price: $69.81 USD 3.71 (5.61%)
Updated May 11, 2021 4:00 PM EDT - Market closed
After-hours: $69.00 -0.81 (-1.16%) May 11, 7:51 PM
Market Cap 6.77B
Revenue (ttm) 89.12M
Net Income (ttm) -109.59M
Shares Out 103.87M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $69.81
Previous Close $66.10
Change ($) 3.71
Change (%) 5.61%
Day's Open 64.15
Day's Range 63.50 - 71.13
Day's Volume 781,756
52-Week Range 30.83 - 92.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals today announced financial results for its fiscal second quarter ended March 31, 2021.

1 week ago - Business Wire

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated wi...

1 week ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Announces Improvement in Fibrosis after ARO-AAT, being co-developed with Takeda, in Patients with the rare genetic Alpha-1 Liver Disease

1 week ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

3 weeks ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $ARWR--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to ut...

3 weeks ago - Business Wire

In Q4 2020, we discussed why Arrowhead stock, a biopharmaceutical company that develops RNA interference therapies, looks attractive despite a stellar 16x move since early 2018. The stock has had a vola...

2 months ago - Forbes

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia

2 months ago - Business Wire

With the trading day about halfway over, the broad markets were trading sideways into the weekend.

Other stocks mentioned: BIIB, FTNT, KSS, PINS, DECK, INFI, IP ...
3 months ago - 24/7 Wall Street

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 566.67% over the past year to ($0.20)...

3 months ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports fiscal 2021 first quarter earnings and holds a conference call

3 months ago - Business Wire

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NA...

3 months ago - GlobeNewsWire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia

3 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021

3 months ago - Business Wire

ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their Intellect...

4 months ago - Seeking Alpha

Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on InvestorPlace.

Other stocks mentioned: DD, IBM, INTC, TMO, ONTO, VECO
4 months ago - InvestorPlace

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

5 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop

5 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited

5 months ago - Business Wire

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...

Other stocks mentioned: ADXS, ALNY
5 months ago - Benzinga

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36% over the past year...

5 months ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020

5 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association

5 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience

5 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences

6 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3

6 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings

6 months ago - Business Wire

These biotechs are fueling up for massive market launches.

Other stocks mentioned: CRSP
6 months ago - The Motley Fool

Despite a 3x growth since the March 18 lows of this year, at the current price of around $60 per share we believe Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interference the...

6 months ago - Forbes

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies th...

Other stocks mentioned: ALKS, NBIX, ACAD, BMRN, IONS
6 months ago - Forbes

Vertex's losses are Arrowhead's gains.

6 months ago - The Motley Fool

Arrowhead Pharmaceuticals establishes deal with Takeda for the use of ARO-AAT in a deal worth up to $1.04 billion.

6 months ago - Seeking Alpha

Arrowhead's New Deal With Takeda Strengthens The Company's Value Proposition

Other stocks mentioned: TAK
6 months ago - Seeking Alpha

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference

7 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports inducement grants

7 months ago - Business Wire

Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher. The post Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting...

7 months ago - InvestorPlace

Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumped. The pos...

7 months ago - Investors Business Daily

The company reported positive interim data from a clinical trial.

7 months ago - The Motley Fool

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT.

7 months ago - 24/7 Wall Street

Arrowhead Pharmaceuticals Is A Smart Long-Term Opportunity

8 months ago - Seeking Alpha

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead appoints veteran pharmaceutical industry executive Oye Olukotun, M.D.

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Janssen present Phase clinical data on hepatitis B treatment JNJ-3989 at EASL International Liver Congress 2020

8 months ago - Business Wire

Arrowhead Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Arrowhead Pharma Shows Improved Relative Price Strength appeared fir...

8 months ago - Investors Business Daily

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at August 2020 conferences

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma

8 months ago - Business Wire

BioBoyScout recently raised his price target on Arrowhead Pharmaceuticals to $107.

8 months ago - Seeking Alpha

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

9 months ago - Business Wire

Most Medical Development & Treatment companies tend not to be involved in the Covid-19 virus vaccine race.

9 months ago - Seeking Alpha

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clin... [Read more...]

Industry
Biotechnology
IPO Date
Jun 16, 1993
CEO
Christopher Anzalone
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
ARWR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 91.08, which is an increase of 30.47% from the latest price.

Price Target
$91.08
(30.47% upside)
Analyst Consensus: Buy